FUL Stock Analysis: H Fuller | NYSE
Specialty Chemicals | NYSE, USA | Market Cap: 2.704m USD | 12M Return: -12.8% | US3596941068 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 46.9M
EPS Trend: 61.4%
Qual. Beats: 0
Rev. Trend: -26.1%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The business is organized into three segments. The Hygiene, Health and Consumable Adhesives segment supplies specialty industrial adhesives (thermoplastic, thermoset, reactive, water-based, and solvent-based) for packaging, converting, nonwoven and hygiene, and medical and beauty applications. The Engineering Adhesives segment offers high-performance bonding products for durable assembly, performance wood and textile, transportation, electronics, clean energy, aerospace and defense, appliance, heavy machinery, and insulating glass markets. The Building Adhesive Solutions segment provides products for commercial roofing, HVAC and insulation applications, as well as caulks and sealants for the consumer and professional trade.
H.B. Fuller distributes its products through direct sales, distributors, and retailers across North America, Latin America, Europe, India, the Middle East, Africa, and the Asia Pacific. The breadth of end markets served is a defining feature of the specialty chemicals business model, with revenue tied to the production volumes and product cycles of a wide range of industrial customers.
- Hygiene segment margins expand on price and mix shift
- Engineering adhesives gain from EV and clean energy growth
- Construction adhesives face U.S. housing demand headwinds
| Net Income: 197.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.54 > 1.0 |
| NWC/Revenue: 18.79% < 20% (prev 17.89%; Δ 0.90% < -1%) |
| CFO/TA 0.05 > 3% & CFO 267.2m > Net Income 197.8m |
| Net Debt (2.02b) to EBITDA (580.7m): 3.47 < 3 |
| Current Ratio: 1.82 > 1.5 & < 3 |
| Outstanding Shares: last quarter (54.9m) vs 12m ago -0.86% < -2% |
| Gross Margin: 32.79% > 18% (prev 30.69%; Δ 2.10% > 0.5%) |
| Asset Turnover: 67.10% > 50% (prev 67.79%; Δ -0.69% > 0%) |
| Interest Coverage Ratio: 2.89 > 6 (EBIT TTM 402.3m / Interest Expense TTM 139.4m) |
| A: 0.12 (Total Current Assets 1.49b - Total Current Liabilities 818.1m) / Total Assets 5.43b |
| B: 0.40 (Retained Earnings 2.15b / Total Assets 5.43b) |
| C: 0.08 (EBIT TTM 402.3m / Avg Total Assets 5.30b) |
| D: 0.67 (Book Value of Equity 2.17b / Total Liabilities 3.26b) |
| Altman-Z'' = 3.31 = A |
| DSRI: 1.13 (Receivables 648.0m/563.6m, Revenue 3.55b/3.50b) |
| GMI: 0.94 (GM 30.69% / 32.79%) |
| AQI: 1.44 (AQ_t 0.55 / AQ_t-1 0.38) |
| SGI: 1.01 (Revenue 3.55b / 3.50b) |
| TATA: -0.01 (NI 197.8m - CFO 267.2m) / TA 5.43b) |
| Beneish M = -2.70 (Cap -4..+1) = A |
As of October 07, 2026, the stock is trading at USD 50.63 with a total of 913,561 shares traded. Over the past week, the price has changed by +2.08%, over one month by -4.54%, over three months by -12.91% and over the past year by -12.80%.
Current recommended Stop Loss: 47.20 (which is 6.8% or 1.9 ATR below the current price).
H Fuller has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy FUL.
- StrongBuy: 5
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 68.3 | 34.9% |
P/E Trailing = 13.7616
P/E Forward = 9.4429
P/S = 0.7608
P/B = 1.3191
P/EG = 2.2026
Revenue TTM = 3.55b USD
EBIT TTM = 402.3m USD
EBITDA TTM = 580.7m USD
Long Term Debt = 2.02b USD (from longTermDebt, last fiscal year)
Short Term Debt = unknown (none)
Debt = 2.11b USD (from shortLongTermDebtTotal, last quarter) + Leases 59.1m
Net Debt = 2.02b USD (calculated: Debt 2.11b - CCE 97.2m)
Enterprise Value = 4.72b USD (2.70b + Debt 2.11b - CCE 97.2m)
Interest Coverage Ratio = 2.89 (Ebit TTM 402.3m / Interest Expense TTM 139.4m)
EV/FCF = 49.95x (Enterprise Value 4.72b / FCF TTM 94.5m)
FCF Yield = 2.00% (FCF TTM 94.5m / Enterprise Value 4.72b)
FCF Margin = 2.66% (FCF TTM 94.5m / Revenue TTM 3.55b)
Net Margin = 5.56% (Net Income TTM 197.8m / Revenue TTM 3.55b)
Gross Margin = 32.79% ((Revenue TTM 3.55b - Cost of Revenue TTM 2.39b) / Revenue TTM)
Gross Margin QoQ = 33.22% (prev 33.91%)
Tobins Q-Ratio = 0.87 (Enterprise Value 4.72b / Total Assets 5.43b)
Interest Expense / Debt = 6.59% (Interest Expense 139.4m / Debt 2.11b)
Taxrate = 26.03% (69.6m / 267.4m)
NOPAT = 297.6m (EBIT 402.3m * (1 - 26.03%))
Current Ratio = 1.82 (Total Current Assets 1.49b / Total Current Liabilities 818.1m)
Debt / Equity = 0.97 (Debt 2.11b / totalStockholderEquity, last quarter 2.17b)
Debt / EBITDA = 3.47 (Net Debt 2.02b / EBITDA 580.7m)
Debt / FCF = 21.34 (Net Debt 2.02b / FCF TTM 94.5m)
Total Stockholder Equity = 2.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.73% (Net Income 197.8m / Total Assets 5.43b)
RoE = 9.51% (Net Income TTM 197.8m / Total Stockholder Equity 2.08b)
RoCE = 9.82% (EBIT 402.3m / Capital Employed (Equity 2.08b + L.T.Debt 2.02b))
RoIC = 6.60% (NOPAT 297.6m / Invested Capital 4.51b)
WACC = 7.21% (E(2.70b)/V(4.82b) * Re(9.03%) + D(2.11b)/V(4.82b) * Rd(6.59%) * (1-Tc(0.26)))
Discount Rate = 9.03% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -86.74 | Cagr: -1.37%
[DCF] Terminal Value 73.10% ; FCFF base≈103.8m ; Y1≈91.0m ; Y5≈73.5m
[DCF] Fair Price = N/A (negative equity: EV 1.18b - Net Debt 2.02b = -836.5m; debt exceeds intrinsic value)
EPS Correlation: 61.39 | EPS CAGR: 5.43% | SUE: 0.52 | # QB: 0
Revenue Correlation: -26.08 | Revenue CAGR: -0.27% | SUE: -0.02 | # QB: 0
EPS current Quarter (2027-02-28): EPS=0.71 | Chg30d=-6.02% | Revisions=+0% | Analysts=4
EPS current Year (2026-11-30): EPS=4.85 | Chg30d=+0.43% | Revisions=+70% | GrowthEPS=+14.4% | GrowthRev=+3.9%
EPS next Year (2027-11-30): EPS=5.18 | Chg30d=-2.70% | Revisions=+44% | GrowthEPS=+6.9% | GrowthRev=+7.5%
[Analyst] Revisions Ratio: +61% (up=13, down=2)